Bluejay director granted 100K options at $2.075

Q: What did BJDX director Fred S. Zeidman acquire in this Form 4?

Fred S. Zeidman was granted 100,000 stock options for Bluejay Diagnostics, Inc. (BJDX). The options relate to Common Stock and represent a compensation-related acquisition rather than an open-market purchase.

Q: What is the exercise price and term of the new BJDX options?

The granted options have an exercise price of $2.075 per share and expire on 2031-08-17. This gives the holder the right to buy BJDX common shares at that price if vesting and exercisability conditions are satisfied.

Q: When do Fred S. Zeidman’s BJDX options vest and become exercisable?

The options vest and become exercisable on the first anniversary of the grant date. However, they are not exercisable unless the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.

Q: What regulatory milestone affects exercisability of these BJDX options?

Exercisability depends on FDA clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. Until this regulatory milestone occurs, the options, even if vested by time, cannot be exercised.

Q: How many BJDX options does Fred S. Zeidman hold after this transaction?

After this grant, Fred S. Zeidman holds 100,000 stock options directly. These options are currently described as out-of-the-money, with vesting and exercisability both subject to time and FDA-related conditions.

Bluejay Diagnostics, Inc. (BJDX) reported that director Fred S. Zeidman received a grant of 100,000 stock options on 2026-08-17.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Bluejay Diagnostics, Inc. (BJDX) reported that director Fred S. Zeidman received a grant of 100,000 stock options on 2026-08-17. These options have an exercise price of $2.075 per share and expire on 2031-08-17. They vest on the first anniversary of the grant date and are not exercisable unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. Following this grant, Zeidman holds 100,000 options directly.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider ZEIDMAN FRED S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 contracts (Direct)

Footnotes (1)

F1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.

Key Figures

Options granted: 100,000 options Exercise price: $2.075 per share Expiration date: 2031-08-17 +2 more

5 metrics

Options granted 100,000 options Stock Option (Right to Buy) granted to director on 2026-08-17

Exercise price $2.075 per share Conversion or exercise price for the granted stock options

Expiration date 2031-08-17 Expiration of the granted stock options

Underlying shares 100,000 shares Common Stock underlying the granted options

Vesting timing First anniversary of grant date Time-based vesting condition for the options

Key Terms

out-of-the-money stock options, point-of-care testing device, U.S. Food and Drug Administration

3 terms

out-of-the-money stock options financial

"Represents out-of-the-money stock options that vest and become exercisable"

point-of-care testing device medical

"approval of the issuer's Symphony IL-6 point-of-care testing device"

U.S. Food and Drug Administration regulatory

"unless and until the U.S. Food and Drug Administration shall have granted"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BJDX director Fred S. Zeidman acquire in this Form 4?

Fred S. Zeidman was granted 100,000 stock options for Bluejay Diagnostics, Inc. (BJDX). The options relate to Common Stock and represent a compensation-related acquisition rather than an open-market purchase.

What is the exercise price and term of the new BJDX options?

The granted options have an exercise price of $2.075 per share and expire on 2031-08-17. This gives the holder the right to buy BJDX common shares at that price if vesting and exercisability conditions are satisfied.

When do Fred S. Zeidman’s BJDX options vest and become exercisable?

The options vest and become exercisable on the first anniversary of the grant date. However, they are not exercisable unless the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.

What regulatory milestone affects exercisability of these BJDX options?

Exercisability depends on FDA clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. Until this regulatory milestone occurs, the options, even if vested by time, cannot be exercised.

How many BJDX options does Fred S. Zeidman hold after this transaction?

After this grant, Fred S. Zeidman holds 100,000 stock options directly. These options are currently described as out-of-the-money, with vesting and exercisability both subject to time and FDA-related conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/18/2026 - 04:17 PM Accepted by SEC EDGAR 08/18/2026 - 04:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZEIDMAN FRED S

(Last)

(First)

(Middle)

C/O BLUEJAY DIAGNOSTICS, INC.

360 MASSACHUSETTS AVENUE, SUITE 203

(Street)

ACTON

MASSACHUSETTS

01720

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bluejay Diagnostics, Inc. [ BJDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.075	08/17/2026		A		100,000		⁽¹⁾	08/17/2031	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.

	/s/ Fred S Zeidman	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR